A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
M.D. Anderson Cancer Center
Genmab
Duke University
AstraZeneca
NeoTX Therapeutics Ltd.
SystImmune Inc.
Vanderbilt-Ingram Cancer Center
Exelixis
Cancer Research UK
University of Alabama at Birmingham
Eli Lilly and Company
Klus Pharma Inc.
Tempus AI
Theratechnologies
Carisma Therapeutics Inc
Comprehensive Support Project for Oncology Research